Market Overview:
The global Dipeptidyl Peptidase-4 (DPP-4) inhibitors market is expected to register a CAGR of 7.5% during the forecast period, 2018–2030. The hospital segment is expected to dominate the market in terms of revenue share, followed by clinic and others segments respectively. North America dominates the global DPP-4 inhibitors market with a revenue share of more than 35%, followed by Europe and Asia Pacific respectively.
 Inhibitors Industry Outlook.svg)
Product Definition:
DPP-4 inhibitors are a class of drugs that work by blocking the DPP-4 enzyme. This enzyme helps to break down certain hormones, including glucagon and insulin. When it is blocked, these hormones can work longer and have a greater effect. DPP-4 inhibitors are used to treat type 2 diabetes mellitus.
Sitagliptin:
The global market for sitagliptin, it's usage and growth factor in DPP-4 inhibitors is expected to witness significant growth over the forecast period. The primary factor that can be attributed to this surge in demand is the patent expiration of popular drugs such as Januvia (Lantus) and Onglyza (Sangamo).
Saxagliptin:
Saxagliptin is a new oral anti-glucocorticoid drug developed to treat the symptoms of corticosteroid withdrawal. It is specifically used in patients who are undergoing treatment for hyperglycemia and have been unable to achieve adequate control of their blood glucose levels with any other medication.
Application Insights:
DPP-4 inhibitors are primarily used in the treatment of diabetes mellitus type 2. The others application segment includes cancer and cardiovascular diseases. In 2017, the hospital application segment dominated the global DPP-4 inhibitors market with a revenue share of over 60%. This is attributed to high adoption rates for antidiabetic drugs in hospitals across various countries such as Germany, Japan and China. Moreover, increasing awareness about lifestyle management and growing incidences of Type 2 diabetes are expected to drive demand for these drugs in hospital applications over the forecast period.
The clinic application segment is anticipated to witness lucrative growth during the study period owing to rising adoption rates for antidiabetic drugs by clinics across various countries such as India, South Africa and Australia due to their low cost compared to hospitalization expenses incurred by patients visiting clinics.
Regional Analysis:
North America dominated the global DPP-4 inhibitors market in 2017. This is attributed to the local presence of key players, high healthcare expenditure and favorable reimbursement policies for innovation and development of new therapies. In addition, increasing prevalence of diabetes is also expected to drive growth over the forecast period. According to a study published in The New England Journal of Medicine in 2015, around 29 million people were diagnosed with diabetes in U.S., while another 86 million people had prediabetes symptoms that required preventive care from primary care providers like physicians and dietitians every year between 2011 and 2014.
Growth Factors:
- Increasing incidence of type 2 diabetes mellitus (T2DM)
- Rising geriatric population
- Growing awareness about the benefits of DPP-4 inhibitors over other antidiabetic therapies
- Technological advancements in the field of DPP-4 inhibitors development
- Launch of novel and improved DPP-4 inhibitors
Scope Of The Report
Report Attributes
Report Details
Report Title
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market Research Report
By Type
Sitagliptin, Saxagliptin, Vildagliptin, Linagliptin
By Application
Hospital, Clinic, Others
By Companies
Eli Lilly, Glaxo Smith Kline, Boehringer, Bristol-Myers Squibb, Pfizer, AstraZeneca, Sanofi, Novo Nordisk, Eli Lilly
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
136
Number of Tables & Figures
96
Customization Available
Yes, the report can be customized as per your need.
Global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market Report Segments:
The global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors market is segmented on the basis of:
Types
Sitagliptin, Saxagliptin, Vildagliptin, Linagliptin
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eli Lilly
- Glaxo Smith Kline
- Boehringer
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Sanofi
- Novo Nordisk
- Eli Lilly
 Inhibitors Market Overview.svg)
Highlights of The Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Sitagliptin
- Saxagliptin
- Vildagliptin
- Linagliptin
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Inhibitors Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
DPP-4 inhibitors are medications that block the activity of DPP-4. This can reduce the amount of peptides (short chains of amino acids) released from cells in response to stimulation by hormones or other factors. DPP-4 inhibitors are used to treat a variety of conditions, including: type 2 diabetes, obesity, and certain cancers.
Some of the key players operating in the dipeptidyl peptidase-4 (dpp-4) inhibitors market are Eli Lilly, Glaxo Smith Kline, Boehringer, Bristol-Myers Squibb, Pfizer, AstraZeneca, Sanofi, Novo Nordisk, Eli Lilly.
The dipeptidyl peptidase-4 (dpp-4) inhibitors market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market Size & Forecast, 2020-2028
4.5.1 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market Size and Y-o-Y Growth
4.5.2 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Sitagliptin
5.2.2 Saxagliptin
5.2.3 Vildagliptin
5.2.4 Linagliptin
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Sitagliptin
9.6.2 Saxagliptin
9.6.3 Vildagliptin
9.6.4 Linagliptin
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Sitagliptin
10.6.2 Saxagliptin
10.6.3 Vildagliptin
10.6.4 Linagliptin
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Sitagliptin
11.6.2 Saxagliptin
11.6.3 Vildagliptin
11.6.4 Linagliptin
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Sitagliptin
12.6.2 Saxagliptin
12.6.3 Vildagliptin
12.6.4 Linagliptin
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Sitagliptin
13.6.2 Saxagliptin
13.6.3 Vildagliptin
13.6.4 Linagliptin
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market: Competitive Dashboard
14.2 Global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Eli Lilly
14.3.2 Glaxo Smith Kline
14.3.3 Boehringer
14.3.4 Bristol-Myers Squibb
14.3.5 Pfizer
14.3.6 AstraZeneca
14.3.7 Sanofi
14.3.8 Novo Nordisk
14.3.9 Eli Lilly
